BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 38134249)

  • 1. CNS Drug Delivery in Stroke: Improving Therapeutic Translation From the Bench to the Bedside.
    Ronaldson PT; Williams EI; Betterton RD; Stanton JA; Nilles KL; Davis TP
    Stroke; 2024 Jan; 55(1):190-202. PubMed ID: 38134249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood-Brain Barrier Transporters: Opportunities for Therapeutic Development in Ischemic Stroke.
    Nilles KL; Williams EI; Betterton RD; Davis TP; Ronaldson PT
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting organic cation transporters at the blood-brain barrier to treat ischemic stroke in rats.
    Stanton JA; Williams EI; Betterton RD; Davis TP; Ronaldson PT
    Exp Neurol; 2022 Nov; 357():114181. PubMed ID: 35905840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood-brain barrier transporters: a translational consideration for CNS delivery of neurotherapeutics.
    Ronaldson PT; Davis TP
    Expert Opin Drug Deliv; 2024; 21(1):71-89. PubMed ID: 38217410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood-Brain Barrier (BBB)-Crossing Strategies for Improved Treatment of CNS Disorders.
    Zhang W
    Handb Exp Pharmacol; 2024; 284():213-230. PubMed ID: 37528323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies.
    Goel H; Kalra V; Verma SK; Dubey SK; Tiwary AK
    J Control Release; 2022 Jan; 341():782-811. PubMed ID: 34906605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood-brain barrier (BBB) to manage neurological disorders.
    Correia AC; Monteiro AR; Silva R; Moreira JN; Sousa Lobo JM; Silva AC
    Adv Drug Deliv Rev; 2022 Oct; 189():114485. PubMed ID: 35970274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transport Mechanisms at the Blood-Brain Barrier and in Cellular Compartments of the Neurovascular Unit: Focus on CNS Delivery of Small Molecule Drugs.
    Ronaldson PT; Davis TP
    Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional Expression of P-glycoprotein and Organic Anion Transporting Polypeptides at the Blood-Brain Barrier: Understanding Transport Mechanisms for Improved CNS Drug Delivery?
    Abdullahi W; Davis TP; Ronaldson PT
    AAPS J; 2017 Jul; 19(4):931-939. PubMed ID: 28447295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of Therapeutic Nanoplatforms as a Potential Candidate for the Treatment of CNS Disorders: Challenges and Possibilities.
    Sa P; Singh P; Dilnawaz F; Sahoo SK
    Curr Pharm Des; 2022; 28(33):2742-2757. PubMed ID: 35909283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Getting into the brain: approaches to enhance brain drug delivery.
    Patel MM; Goyal BR; Bhadada SV; Bhatt JS; Amin AF
    CNS Drugs; 2009; 23(1):35-58. PubMed ID: 19062774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approaches to CNS Drug Delivery with a Focus on Transporter-Mediated Transcytosis.
    Abdul Razzak R; Florence GJ; Gunn-Moore FJ
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transporter-Mediated Delivery of Small Molecule Drugs to the Brain: A Critical Mechanism That Can Advance Therapeutic Development for Ischemic Stroke.
    Williams EI; Betterton RD; Davis TP; Ronaldson PT
    Pharmaceutics; 2020 Feb; 12(2):. PubMed ID: 32075088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective drug delivery approaches to lesioned brain through blood brain barrier disruption.
    Al-Ahmady ZS
    Expert Opin Drug Deliv; 2018 Apr; 15(4):335-349. PubMed ID: 29466890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease.
    Hanson LR; Frey WH
    BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S5. PubMed ID: 19091002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracellular Vesicles as Drug Delivery Vehicles to the Central Nervous System.
    Shahjin F; Chand S; Yelamanchili SV
    J Neuroimmune Pharmacol; 2020 Sep; 15(3):443-458. PubMed ID: 31485884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the blood-brain barrier for the delivery of stroke therapies.
    D'Souza A; Dave KM; Stetler RA; S Manickam D
    Adv Drug Deliv Rev; 2021 Apr; 171():332-351. PubMed ID: 33497734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke.
    Ronaldson PT; Davis TP
    Curr Pharm Des; 2012; 18(25):3624-44. PubMed ID: 22574987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smart Strategies for Therapeutic Agent Delivery into Brain across the Blood-Brain Barrier Using Receptor-Mediated Transcytosis.
    Tashima T
    Chem Pharm Bull (Tokyo); 2020; 68(4):316-325. PubMed ID: 32238649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced drug delivery system against ischemic stroke.
    Zhang S; Zhou Y; Li R; Chen Z; Fan X
    J Control Release; 2022 Apr; 344():173-201. PubMed ID: 35248645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.